Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
European Journal of Nuclear Medicine and Molecular Imaging
Published in: European Journal of Nuclear Medicine and Molecular Imaging 1/2017

01-01-2017 | Editorial

Segmental 18F-FDG-PET/CT in a single pulmonary nodule: a better cost/effectiveness strategy

Authors: Marco Spadafora, Leonardo Pace, Luigi Mansi

Published in: European Journal of Nuclear Medicine and Molecular Imaging | Issue 1/2017

Login to get access

Excerpt

A solitary pulmonary nodule (SPN) is one of the most frequent computed tomography (CT) incidental findings. Its characterization is of paramount relevance, since prognosis of malignant pulmonary lesions is strictly related to a tumor’s dimension at diagnosis [1, 2]. Actually, although lung cancer is the leading cause of cancer death worldwide, a favorable 5-year survival rate up to 80 % [3] after surgical resection at an earlier stage, has been observed. Thus, it appears mandatory to define appropriate diagnostic strategies for an early characterization of SPN, and diagnostic imaging plays a major role in this process. …
Literature
1.
Port JL, Kent MS, Korst RJ, Libby D, Pasmantier M, Altorki NK. Tumor size predicts survival within stage IA non-small cell lung cancer. Chest. 2003;124:1828–33.CrossRefPubMed
2.
Goldstraw P, Crowley JJ. The International Association for the Study of Lung Cancer international staging project on lung cancer. J Thorac Oncol. 2006;1:281–6.CrossRef
3.
4.
5.
Sullivan R, Peppercorn J, Sikora K, et al. Delivering affordable cancer care in high-income countries. Lancet Oncol. 2011;12:933–80.CrossRefPubMed
6.
Callister MEJ, Baldwin DR, Akram AR, et al. British Thoracic Society guidelines for the investigation and management of pulmonary nodules. Thorax. 2015;70:ii1–ii54.CrossRefPubMed
7.
Gould MK, Donington J, Lynch WR, et al. Evaluation of individuals with pulmonary nodules: when is it lung cancer? Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2013;143(suppl5):93–120.CrossRef
8.
Álvarez Martínez CJ, Bastarrika Alemañ G, Vicente CDJ, et al. Guideline on management of solitary pulmonary nodule. Arch Bronconeumol. 2014;50:285–93.CrossRefPubMed
9.
Jeong YJ, Yi CA, Lee KS. Solitary pulmonary nodules: detection, characterization, and guidance for further diagnostic workup and treatment. AJR. 2007;188:57–68.CrossRefPubMed
10.
Gould MK, Fletcher J, Iannettoni MD, et al. Evaluation of patients with pulmonary nodules: when is it lung cancer?: ACCP evidence-based clinical practice guidelines (2nd edition). Chest. 2007;132 suppl 3:108–30.CrossRef
11.
Huang B, Law MWM, Khong PL. Whole-Body PET/CT scanning: estimation of radiation dose and cancer risk. Radiology. 2009;251:166–74.CrossRefPubMed
12.
Brix G, Lechel U, Glatting G, et al. Radiation exposure of patients undergoing whole-body dual-modality 18F-FDG PET/CT examinations. J Nucl Med. 2005;46:608–13.PubMed
13.
Yi CA, Lee KS, Kim BT, et al. Tissue characterization of solitary pulmonary nodule: comparative study between helical dynamic CT and integrated PET/CT. J Nucl Med. 2006;47:443–50.PubMed
14.
Al-Ameri A, Malhotra P, Thygesen H, et al. Risk of malignancy in pulmonary nodules: A validation study of four prediction models. Lung Cancer. 2015;89:27–30.CrossRefPubMed
15.
Aberle DR, Adams AM, Berg CD, et al. National Lung Screening Trial Research Team. Reduced lung-cancer mortality with low-dose computed tomographic screening. N Engl J Med. 2011;365:395–409.CrossRefPubMed
16.
Salvatierra A, Baamonde C, Llamas JM, Cruz F, Lopez-Pujol J. Extra-thoracic staging of bronchogenic carcinoma. Chest. 1990;97:1052–8.CrossRefPubMed
17.
18.
Tasdemir B, Urakci Z, Dostbil Z, et al. Effectiveness of the addition of the brain region to the FDG-PET/CT imaging area in patients with suspected or diagnosed lung cancer. Radiol Med. 2015.
19.
Patz Jr EF, Pinsky P, Gatsonis C, et al. Over-diagnosis manuscript writing team over-diagnosis in low-dose computed tomography screening for lung cancer. JAMA Intern Med. 2014;174:269–74.CrossRefPubMedPubMedCentral
20.
Boellaard R, Delgado-Bolton R, Oyen WJG, et al. FDG PET/CT: EANM procedure guidelines for tumour imaging: version 2.0. Eur J Nucl Med Mol Imaging. 2015;42:328–54.CrossRefPubMed
21.
Erasmus JJ, Connolly JE, McAdams HP, Roggli VL. Solitary pulmonary nodules: Part I. Morphologic evaluation for differentiation of benign and malignant lesions. Radiographics. 2000;20:43–58.CrossRefPubMed
22.
Osman MM, Cohade C, Nakamoto Y, Wahl RL. Respiratory motion artifacts on PET emission images obtained using CT attenuation correction on PET-CT. Eur J Nucl Med Mol Imaging. 2003;30:603–6.CrossRefPubMed
23.
Guerra L, De Ponti E, Elisei F, et al. Respiratory gated PET/CT in a European multicentre retrospective study: added diagnostic value in detection and characterization of lung lesions. Eur J Nucl Med Mol Imaging. 2012;39:1381–90.CrossRefPubMed
24.
Brenner DJ. Radiation risks potentially associated with low-dose CT screening of adult smokers for lung cancer. Radiology. 2004;231:440–5.CrossRefPubMed
25.
Board of Radiation Effects Research Division on Earth and Life Sciences National Research Council of the National Academies. Health Risks from Exposure to Low Levels of Ionizing Radiation: BEIR VII Phase 2. Washington, D.C.: The National Academies Press; 2006.
26.
Zanzonico P, Stabin MG. Quantitative benefit-risk analysis of medical radiation exposures. Semin Nucl Med. 2014;44:210–4.CrossRefPubMed
27.
Isbell JM, Deppen S, Putnam JB, et al. Existing general population models inaccurately predict lung cancer risk in patients referred for surgical evaluation. Ann Thorac Surg. 2011;91:227–33.CrossRefPubMedPubMedCentral
28.
Evangelista L, Panunzio A, Polverosi R, et al. Indeterminate lung nodules in cancer patients: pretest probability of malignancy and the role of 18F-FDG PET/CT. AJR. 2014;202:507–14.CrossRefPubMed
Metadata
Title
Segmental 18F-FDG-PET/CT in a single pulmonary nodule: a better cost/effectiveness strategy
Authors
Marco Spadafora
Leonardo Pace
Luigi Mansi
Publication date
01-01-2017
Publisher
Springer Berlin Heidelberg
Published in
European Journal of Nuclear Medicine and Molecular Imaging / Issue 1/2017
Print ISSN: 1619-7070
Electronic ISSN: 1619-7089
DOI
https://doi.org/10.1007/s00259-016-3532-0

Other articles of this Issue 1/2017

European Journal of Nuclear Medicine and Molecular Imaging 1/2017 Go to the issue

Erratum

Erratum to: Performance of cardiac cadmium-zinc-telluride gamma camera imaging in coronary artery disease: a review from the cardiovascular committee of the European Association of Nuclear Medicine (EANM)

Original Article

Prognostic impact of tumour burden assessed by metabolic tumour volume on FDG PET/CT in anal canal cancer

Erratum

Erratum to: Characterization of the radiolabeled metabolite of tau PET tracer 18F-THK5351

Letter to the Editor

177Lu-PSMA-617 radioligand therapy of mCRPC: evaluation criteria of response

Original Article

Metabolic tumor volume predicts overall survival and local control in patients with stage III non-small cell lung cancer treated in ACRIN 6668/RTOG 0235

Editorial Commentary

Editorial: Listen to your belly, fat is not your foe!